Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty

Clinical Research in Cardiology

Volumn 104, Issue 3, 2015, Pages 217-225

  Kleber, Franz X ^a   Schulz, Antonia ^a   Waliszewski, Matthias ^b   Hauschild, Telse ^a,c   Böhm, Michael ^d   Dietz, Ulrich ^e   Cremers, Bodo ^d   Scheller, Bruno ^d   Clever, Yvonne P ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Medical Scientific Affairs   (Germany)

^c Ernst von Bergmann Klinikum   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

Balloon angioplasty; Drug coated balloon; Late lumen enlargement; Vascular remodelling

Indexed keywords

ACETYLSALICYLIC ACID; PACLITAXEL; BIOMATERIAL; CARDIOVASCULAR AGENT;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY LATE LUMEN ENLARGEMENT; DRUG COATED BALLOON; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; DEVICES; DRUG EFFECTS; HEART CATHETER; HYPERPLASIA; MIDDLE AGED; NEOINTIMA; PATHOPHYSIOLOGY; RADIOGRAPHY; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASCULAR REMODELING;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIAC CATHETERS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; FEMALE; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; NEOINTIMA; PACLITAXEL; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR REMODELING;

EID: 84925490457     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-014-0775-2     Document Type: Article

References (52)

1. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al (2006) American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47:e1–e121
2. Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31:2501–2555
3. Brophy JM, Belisle P, Joseph L (2003) Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 138:777–786
4. Al Suwaidi J, Holmes DR Jr, Salam AM et al (2004) Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J 147:815–822
5. Holmes DR Jr, Vlietstra RE, Smith HC et al (1984) Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 53:77C–81C
6. Cremers B, Toner JL, Schwartz LB et al (2012) Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol 101(6):469–476
7. Cremers B, Kelsch B, Clever YP et al (2012) Inhibition of neointimal proliferation after bare metal stent implantation with low-pressure drug delivery using a paclitaxel-coated balloon in porcine coronary arteries. Clin Res Cardiol 101(5):385–391
8. Scheller B, Hehrlein C, Bocksch W et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124
9. Unverdorben M, Vallbracht C, Cremers B et al (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986–2994
10. Navarese EP, Austin D, Gurbel PA et al (2013) Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clin Res Cardiol 102(4):279–287
11. Bonaventura K, Leber AW, Sohns C et al (2012) Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol 101(7):573–584
12. Wöhrle J, Zadura M, Möbius-Winkler S et al (2012) SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol 60:1733–1738
13. Scheller B, Fischer D, Clever YP et al (2013) Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months. Clin Res Cardiol 102(6):469–472
14. Kleber FX, Mathey DG, Rittger H et al (2011) How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention 7(Suppl K):K125–K128
15. Kleber FX, Rittger H, Bonaventura K et al (2013) Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol 102(11):785–797
16. Huber MS, Mooney JF, Madison J et al (1991) Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol 68:467–471
17. Hausleiter J, Jost S, Nolte CW et al (1997) Comparative in vitro validation of eight first- and second-generation quantitative coronary angiography systems. Coron Artery Dis 8:83–90
18. Dietz U, Rupprecht HJ, Brennecke R et al (1997) Comparison of QCA systems. Int J Card Imaging 13:271–280
19. Herrington D, Walford G (1993) Optimal frame selection for QCA. In: Reiber JHC, Serruys PW (eds) Advances in quantitative coronary arteriography. Kluwer Academic Publishers, Dordrecht, pp 125–135
20. Reiber JH, van Eldik-Helleman P, Visser-Akkerman N et al (1988) Variabilities in measurement of coronary arterial dimensions resulting from variations in cineframe selection. Cathet Cardiovasc Diagn 14:221–228
21. Haude M, Erbel R, Issa H et al (1993) Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents. J Am Coll Cardiol 21:26–34
22. Sigwart U, Puel J, Mirkovitch V et al (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316:701–706
23. Serruys PW, de Jaegere P, Kiemeneij F et al (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489–495
24. Brener SJ, Prasad AJ, Khan Z et al (2011) The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. Atherosclerosis 214:158–162
25. Chevalier B, Silber S, Park SJ, NOBORI 1 Clinical Investigators et al (2009) Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial–Phase 2. Circ Cardiovasc Interv 2:188–195
26. Bondesson P, Lagerqvist B, James SK et al (2012) Comparison of two drug-eluting balloons: a report from the SCAAR registry. EuroIntervention 8:444–449
27. Glagov S, Weisenberg E, Zarins CK et al (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371–1375
28. Kakuta T, Currier JW, Haudenschild CC et al (1994) Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 89:2809–2815
29. Heldman AW, Cheng L, Jenkins GM et al (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289–2295
30. Habara S, Mitsudo K, Kadota K et al (2011) Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 4:149–154
31. Byrne RA, Neumann FJ, Mehilli J, ISAR-DESIRE 3 investigators et al (2013) Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 381:461–467
32. Latib A, Colombo A, Castriota F et al (2012) A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 60:2473–2480
33. Rittger H, Brachmann J, Sinha AM et al (2012) A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 59:1377–1382
34. Clever YP, Cremers B, von Scheidt W et al (2014) Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. Clin Res Cardiol 103(1):21–27
35. Werk M, Albrecht T, Meyer DR et al (2012) Paclitaxel-coated balloons reduce Restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 5:831–840
36. Tepe G, Zeller T, Albrecht T et al (2008) Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 358:689–699
37. Werk M, Langner S, Reinkensmeier B et al (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118:1358–1365
38. Pires NM, Eefting D, de Vries MR et al (2007) Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 93:922–927
39. Vogt F, Stein A, Rettemeier G et al (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330–1340
40. Speck U, Cremers B, Kelsch B et al (2012) Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv 5:392–400
41. Axel DI, Kunert W, Göggelmann C et al (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:636–645
42. Ako J, Morino Y, Honda Y et al (2005) Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 46:1002–1005
43. Hou D, Rogers PI, Toleikis PM et al (2000) Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation 102:1575–1581
44. Diletti R, Serruys PW, Farooq V et al (2012) ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 164:654–663
45. Hirshfeld JW Jr, Schwartz JS, Jugo R et al (1991) Clinical and angiographic determinants of primary coronary angioplasty success. M-HEART Investigators. J Am Coll Cardiol 17:22–28
46. Lam JY, Chesebro JH, Steele PM et al (1986) Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 8:1380–1386
47. Chesebro JH, Lam JY, Badimon L et al (1987) Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am J Cardiol 60:10B–16B
48. Serruys PW, Luijten HE, Beatt KJ et al (1988) Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 77:361–371
49. Zeymer U, Waliszewski M, Spiecker M et al (2014) Prospective ‘real world’ registry for the use of the ‘PCB only’ strategy in small vessel de novo lesions. Heart 100(4):311–316
50. Currier JW, Faxon DP (1995) Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 25:516–520
51. Leimgruber PP, Roubin GS, Anderson HV et al (1985) Influence of intimal dissection on restenosis after successful coronary angioplasty. Circulation 72:530–535
52. Poerner TC, Otto S, Gassdorf J et al (2011) A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods. EuroIntervention 7(Suppl K):K93–K99